Princess Margaret, Vall d’Hebron Partner to Advance Personalized Cancer Medicine


Two internationally-acclaimed cancer centres announced a partnership today to accelerate academic and clinical research to advance personalized, targeted therapies against cancer.

The partners – Princess Margaret Cancer Centre and Vall d'Hebron Institute of Oncology (VHIO), Barcelona – signed a Memorandum of Understanding (MOU) in Toronto establishing the principles and framework for their collaboration.

Signing on behalf of The Princess Margaret, Medical Director Dr. Mary Gospodarowicz said: "Our organizations share a common purpose and vision to pool our knowledge, broad spectrum of expertise and commitment to research to promote and disseminate best practices and innovation in cancer care globally." 

"This is how we can provide world-class cancer research and the best possible care to benefit patients well beyond the walls of our individual centres." 

Signing on behalf of VHIO, Director Dr. Josep Tabernero said: "As two leading comprehensive cancer centers, we share several research strengths and synergies.

"VHIO´s cancer science of excellence coupled with The Princess Margaret´s expertise in the realm of cancer care diagnostics and therapeutics will undoubtedly represent an important forward step in advancing cancer research and developing more effective anti-cancer therapies."

Under terms of the MOU, the two centres will exchange information about patient care, research and education programs. They will also share information about best practices in clinical research and clinical trials. As well as support innovation in cancer education and training programs by encouraging academic collaborations, promoting faculty visits and facilitating exchange visits among students and trainees.

L to R:  Dr. Mary Gospodarowicz, Medical Director, Princess Margaret Cancer Centre,
Dr. Josep Tabernero, Director, Vall d'Hebron Institute of Oncology;
Dr. Peter Pisters, President and CEO, University Health Network.